Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
about
Targeted delivery of radioprotective agents to mitochondriaCombination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivoPersonalized Combined Modality Therapy for Locally Advanced Non-small Cell Lung Cancer.Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapyPreclinical evaluation of sunitinib, a multi-tyrosine kinase inhibitor, as a radiosensitizer for human prostate cancer.Combined vaccination with HER-2 peptide followed by therapy with VEGF peptide mimics exerts effective anti-tumor and anti-angiogenic effects in vitro and in vivo.Malignant gliomas: strategies to increase the effectiveness of targeted molecular treatment.Novel therapies for meningiomas.Antiangiogenic effects of noscapine enhance radioresponse for GL261 tumors.Novel mutant-enriched sequencing identified high frequency of PIK3CA mutations in pharyngeal cancer.Improved sensitization effect of sunitinib in cancer cells of the esophagus under hypoxic microenviroment.The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies.Association of ribosomal protein S6 kinase 1 with cellular radiosensitivity of non-small lung cancer.Kinomic profiling approach identifies Trk as a novel radiation modulator.NVP-BEZ235 and NVP-BGT226, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitors, enhance tumor and endothelial cell radiosensitivityIncreased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer.Paeonol enhances the sensitivity of human ovarian cancer cells to radiotherapy-induced apoptosis due to downregulation of the phosphatidylinositol-3-kinase/Akt/phosphatase and tensin homolog pathway and inhibition of vascular endothelial growth factPI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis.Tumor heterogeneity revealed by KRAS, BRAF, and PIK3CA pyrosequencing: KRAS and PIK3CA intratumor mutation profile differences and their therapeutic implications.Thermoradiotherapy is underutilized for the treatment of cancer
P2860
Q33972592-83D3AE3C-AF41-4AE3-8DA2-FEEBFECFB5D6Q34787422-14563430-0B2D-43F1-9897-C0B36A9CD1CDQ36089579-0D9B5AF9-1689-4ACE-996D-70D416CA9EB7Q36116250-8453B7C1-EFD0-4542-BF86-BD71FE2EBD94Q36388217-3DF527B6-32DF-4118-87BC-3A632D9D8040Q36388501-39740153-B053-4C10-A183-2CB0FE80B813Q36499234-7942BB1F-6E60-486D-8130-4C96220D9B6CQ36641500-B69E575A-B0C5-46CA-9653-375AB7D49F07Q36947173-3060E3C2-4CC1-4340-8398-CB6522C4DFECQ37474182-6922B146-E459-4CB0-874C-CD0D1AE45529Q37582179-ECC81DDA-B93E-455D-A261-C11A8A01BAE1Q38028791-5E5588C7-5CB3-4A18-AF90-EF8D1029799EQ38712997-8023ACF8-3BF5-4EF0-82F2-A89ACC801AC0Q39353324-D58D25FE-AA99-47BB-BFDE-8DE017E7FECBQ39373143-3292F673-219E-4F48-8EA3-14907ED2E13EQ39402103-EC1D9EA7-CC21-4402-A056-1CB8BF26EB43Q41623770-4B6B349F-F25B-4930-B2AA-A38CE0F62E4BQ42011584-D5850B5E-BBFC-447E-9597-23BE4EB15D0AQ54389429-267B5924-0570-4A09-AE33-351FAD250C1FQ58089808-6334CFAE-DCEA-4AD1-9251-F0BDFEF791BE
P2860
Molecular strategies targeting the host component of cancer to enhance tumor response to radiation therapy.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
2006年學術文章
@zh
2006年學術文章
@zh-hant
name
Molecular strategies targeting ...... response to radiation therapy.
@ast
Molecular strategies targeting ...... response to radiation therapy.
@en
type
label
Molecular strategies targeting ...... response to radiation therapy.
@ast
Molecular strategies targeting ...... response to radiation therapy.
@en
prefLabel
Molecular strategies targeting ...... response to radiation therapy.
@ast
Molecular strategies targeting ...... response to radiation therapy.
@en
P2093
P1476
Molecular strategies targeting ...... response to radiation therapy.
@en
P2093
Dennis E Hallahan
Dong Wook Kim
Jessica Huamani
P356
10.1016/J.IJROBP.2005.02.008
P407
P577
2006-01-01T00:00:00Z